Literature DB >> 27448155

The effects of n-3 long-chain polyunsaturated fatty acid supplementation on AGEs and sRAGE in type 2 diabetes mellitus.

Asuman Kurt1, Gülnur Andican2, Zeynep Oşar Siva3, Ahat Andican4, Gülden Burcak1.   

Abstract

In diabetes mellitus, chronic hyperglycemia leads to formation of advanced glycation end products (AGEs). Binding of AGEs to receptors of AGE (RAGE) causes deleterious effects. In populations with a high consumption of n-3 long-chain polyunsaturated fatty acids, a lower prevalence of diabetes mellitus has been reported. We aimed to investigate the effects of n-3 fatty acid (EPA and DHA) supplementation on the levels of AGEs (carboxymethyl lysine (CML) and pentosidine), sRAGE, and nuclear factor kappa B (NF-kB) in type 2 diabetes mellitus (T2DM). T2DM patients (n = 38) treated with oral hypoglycemic agents, without insulin were supplemented with n-3 fatty acids (1.2 g/day) for 2 months. Plasma CML, pentosidine, sRAGE, and NF-kB levels were measured by ELISA both before and after the supplementation. n-3 fatty acid supplementation significantly reduced fasting glucose (p < 0.01), glycated hemoglobin (HbA1c) (p < 0.05), and pentosidine (p < 0.05) levels. The supplementation induced percentage changes in pentosidine and HbA1c and in pentosidine and creatinine were observed to be correlated (r = 0.349, p < 0.05) and (r = 0.377, p < 0.05), respectively. Waist circumference and systolic and diastolic pressures were significantly decreased due to n-3 supplementation (p < 0.001, p < 0.01, p < 0.01), respectively. Our results show that supplementation with n-3 fatty acid has beneficial effects on waist circumference; systolic and diastolic blood pressures; and the levels of glucose, HbA1c, and pentosidine in T2DM patients. However, the supplementation failed to decrease these parameters to the reference ranges for healthy subjects. In addition, the supplementation did not appear to induce any significant differences in CML, sRAGE, or NF-kB.

Entities:  

Keywords:  AGE; NF-kB; RAGE; Type 2 diabetes; n-3 long-chain fatty acids

Mesh:

Substances:

Year:  2016        PMID: 27448155     DOI: 10.1007/s13105-016-0506-4

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  40 in total

Review 1.  n-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data.

Authors:  Raffaele De Caterina; Rosalinda Madonna; Alessandra Bertolotto; Erik Berg Schmidt
Journal:  Diabetes Care       Date:  2007-01-24       Impact factor: 19.112

2.  Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes.

Authors:  Sho-ichi Yamagishi; Tsutomu Imaizumi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-06       Impact factor: 8.311

3.  A protein-enriched low glycemic index diet with omega-3 polyunsaturated fatty acid supplementation exerts beneficial effects on metabolic control in type 2 diabetes.

Authors:  Simone M Moosheer; Wolfgang Waldschütz; Bianca K Itariu; Helmut Brath; Thomas M Stulnig
Journal:  Prim Care Diabetes       Date:  2014-03-19       Impact factor: 2.459

Review 4.  Waist circumference threshold values for type 2 diabetes risk.

Authors:  Karl E Friedl
Journal:  J Diabetes Sci Technol       Date:  2009-07-01

5.  N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins.

Authors:  S Reddy; J Bichler; K J Wells-Knecht; S R Thorpe; J W Baynes
Journal:  Biochemistry       Date:  1995-08-29       Impact factor: 3.162

6.  Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.

Authors:  K C B Tan; S W M Shiu; W S Chow; L Leng; R Bucala; D J Betteridge
Journal:  Diabetologia       Date:  2006-09-13       Impact factor: 10.122

7.  Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association.

Authors:  John P Bantle; Judith Wylie-Rosett; Ann L Albright; Caroline M Apovian; Nathaniel G Clark; Marion J Franz; Byron J Hoogwerf; Alice H Lichtenstein; Elizabeth Mayer-Davis; Arshag D Mooradian; Madelyn L Wheeler
Journal:  Diabetes Care       Date:  2008-01       Impact factor: 19.112

8.  Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes.

Authors:  K C B Tan; W S Chow; A W K Tso; A Xu; H F Tse; R L C Hoo; D J Betteridge; K S L Lam
Journal:  Diabetologia       Date:  2007-07-18       Impact factor: 10.122

9.  Identification, classification, and expression of RAGE gene splice variants.

Authors:  Barry I Hudson; Angela M Carter; Evis Harja; Anastasia Z Kalea; Maria Arriero; Hojin Yang; Peter J Grant; Ann Marie Schmidt
Journal:  FASEB J       Date:  2007-12-18       Impact factor: 5.191

10.  Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity: importance of hepatic lipogenesis.

Authors:  Ayumi Sato; Hiroyuki Kawano; Tatsuto Notsu; Masahiko Ohta; Masanori Nakakuki; Kiyoshi Mizuguchi; Michiko Itoh; Takayoshi Suganami; Yoshihiro Ogawa
Journal:  Diabetes       Date:  2010-08-03       Impact factor: 9.461

View more
  3 in total

1.  Role of saturated and unsaturated fatty acids on dicarbonyl-albumin derived advanced glycation end products in vitro.

Authors:  Brock Peake; Maulik Ghetia; Cobus Gerber; Maurizio Costabile; Permal Deo
Journal:  Amino Acids       Date:  2021-08-21       Impact factor: 3.520

Review 2.  An Improvement of Cardiovascular Risk Factors by Omega-3 Polyunsaturated Fatty Acids.

Authors:  Hidekatsu Yanai; Yoshinori Masui; Hisayuki Katsuyama; Hiroki Adachi; Akiko Kawaguchi; Mariko Hakoshima; Yoko Waragai; Tadanao Harigae; Akahito Sako
Journal:  J Clin Med Res       Date:  2018-02-18

3.  Advanced glycation end product levels were correlated with inflammation and carotid atherosclerosis in type 2 diabetes patients.

Authors:  Jie Li; Haiyan Shangguan; Xiaoqian Chen; Xiao Ye; Bin Zhong; Pen Chen; Yamei Wang; Bin Xin; Yan Bi; Dalong Zhu
Journal:  Open Life Sci       Date:  2020-06-11       Impact factor: 0.938

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.